Pharnext: registration dossiers prepared for Charcot disease
While its Phase III study did not demonstrate a significantly different clinical response between patients treated and those on placebo, sub-group analyses do suggest a signal of efficacy, explains the biotech in a press release.
The biopharmaceutical company claims to have observed a better response in treated patients with a body mass index of less than 25, or in patients aged under 45.
Furthermore, it appears that in some centers, patients received only placebo, and in others, patients received only PXT3003 treatment, again resulting in a statistically significant difference.
In view of these new results, Pharnext believes there is a chance of
agreeing a registration process in Charcot-Marie-Tooth type 1A disease with the US FDA and the European Union.
Following these announcements, the share price climbed 33% late Tuesday morning on the Paris Bourse.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction